Logo image of BFRI

BIOFRONTERA INC (BFRI) Stock Fundamental Analysis

NASDAQ:BFRI - Nasdaq - US09077D2099 - Common Stock - Currency: USD

1.11  -0.04 (-3.48%)

After market: 1.12 +0.01 (+0.9%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BFRI. BFRI was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of BFRI is average, but there are quite some concerns on its profitability. BFRI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BFRI has reported negative net income.
BFRI had a negative operating cash flow in the past year.
In the past 5 years BFRI always reported negative net income.
In the past 5 years BFRI always reported negative operating cash flow.
BFRI Yearly Net Income VS EBIT VS OCF VS FCFBFRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of BFRI (-69.33%) is worse than 70.81% of its industry peers.
BFRI's Return On Equity of -232.13% is on the low side compared to the rest of the industry. BFRI is outperformed by 73.51% of its industry peers.
Industry RankSector Rank
ROA -69.33%
ROE -232.13%
ROIC N/A
ROA(3y)-48.06%
ROA(5y)-45.58%
ROE(3y)-251.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BFRI Yearly ROA, ROE, ROICBFRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

BFRI has a Gross Margin (47.11%) which is comparable to the rest of the industry.
BFRI's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.02%
GM growth 5YN/A
BFRI Yearly Profit, Operating, Gross MarginsBFRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BFRI has been increased compared to 1 year ago.
BFRI has a worse debt/assets ratio than last year.
BFRI Yearly Shares OutstandingBFRI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500K 1M 1.5M
BFRI Yearly Total Debt VS Total AssetsBFRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -9.51, we must say that BFRI is in the distress zone and has some risk of bankruptcy.
BFRI has a worse Altman-Z score (-9.51) than 73.51% of its industry peers.
There is no outstanding debt for BFRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.51
ROIC/WACCN/A
WACC9.68%
BFRI Yearly LT Debt VS Equity VS FCFBFRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

BFRI has a Current Ratio of 1.53. This is a normal value and indicates that BFRI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.53, BFRI is doing worse than 71.89% of the companies in the same industry.
A Quick Ratio of 0.94 indicates that BFRI may have some problems paying its short term obligations.
With a Quick ratio value of 0.94, BFRI is not doing good in the industry: 82.16% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 0.94
BFRI Yearly Current Assets VS Current LiabilitesBFRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

BFRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.83%, which is quite impressive.
The Revenue has been growing slightly by 5.17% in the past year.
BFRI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.81% yearly.
EPS 1Y (TTM)71.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.88%
Revenue 1Y (TTM)5.17%
Revenue growth 3Y21.81%
Revenue growth 5YN/A
Sales Q2Q%1.3%

3.2 Future

Based on estimates for the next years, BFRI will show a very strong growth in Earnings Per Share. The EPS will grow by 26.03% on average per year.
BFRI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.63% yearly.
EPS Next Y83.94%
EPS Next 2Y39.82%
EPS Next 3Y26.03%
EPS Next 5YN/A
Revenue Next Year12.29%
Revenue Next 2Y15.94%
Revenue Next 3Y19.54%
Revenue Next 5Y22.63%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BFRI Yearly Revenue VS EstimatesBFRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
BFRI Yearly EPS VS EstimatesBFRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BFRI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BFRI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BFRI Price Earnings VS Forward Price EarningsBFRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BFRI Per share dataBFRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

BFRI's earnings are expected to grow with 26.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.82%
EPS Next 3Y26.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BFRI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA INC

NASDAQ:BFRI (2/21/2025, 8:03:13 PM)

After market: 1.12 +0.01 (+0.9%)

1.11

-0.04 (-3.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners24.39%
Inst Owner Change68.68%
Ins Owners7.19%
Ins Owner Change0%
Market Cap8.60M
Analysts82.5
Price Target11.73 (956.76%)
Short Float %4.24%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)39.28%
Min EPS beat(2)-15.06%
Max EPS beat(2)93.63%
EPS beat(4)1
Avg EPS beat(4)-27.76%
Min EPS beat(4)-141.33%
Max EPS beat(4)93.63%
EPS beat(8)1
Avg EPS beat(8)-31.32%
EPS beat(12)4
Avg EPS beat(12)-7.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.03%
Min Revenue beat(2)-11.71%
Max Revenue beat(2)-6.36%
Revenue beat(4)0
Avg Revenue beat(4)-14.11%
Min Revenue beat(4)-28.55%
Max Revenue beat(4)-6.36%
Revenue beat(8)1
Avg Revenue beat(8)-8.84%
Revenue beat(12)1
Avg Revenue beat(12)-6.85%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-110.2%
EPS NY rev (1m)0%
EPS NY rev (3m)5.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 1.57
EV/EBITDA N/A
EPS(TTM)-5.71
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-2.34
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS4.56
BVpS0.71
TBVpS0.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.33%
ROE -232.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.11%
FCFM N/A
ROA(3y)-48.06%
ROA(5y)-45.58%
ROE(3y)-251.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.02%
GM growth 5YN/A
F-Score4
Asset Turnover1.91
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.57%
Cap/Sales 0.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 0.94
Altman-Z -9.51
F-Score4
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)3.51%
Cap/Depr(5y)18.47%
Cap/Sales(3y)0.07%
Cap/Sales(5y)0.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.88%
EPS Next Y83.94%
EPS Next 2Y39.82%
EPS Next 3Y26.03%
EPS Next 5YN/A
Revenue 1Y (TTM)5.17%
Revenue growth 3Y21.81%
Revenue growth 5YN/A
Sales Q2Q%1.3%
Revenue Next Year12.29%
Revenue Next 2Y15.94%
Revenue Next 3Y19.54%
Revenue Next 5Y22.63%
EBIT growth 1Y16.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.35%
OCF growth 3YN/A
OCF growth 5YN/A